Business Wire

BAT

Share
BAT Highlights Serious Inaccuracies in EU e-Cigarette Review

BAT has called on a European Commission scientific committee to enhance the quality of its ongoing review into e-cigarettes. BAT highlighted several serious flaws, the details of which it makes public today . The results of the review may pave the way for revisions to rules that affect millions of vapers across the EU.

The SCHEER Committee (Scientific Committee on Health, Environmental and Emerging Risks ) is an advisory body that was tasked with producing a scientific review of the health effects of e-cigarettes as part of the European Commission’s forthcoming review of the Tobacco Products Directive. The consultation period for this review has now closed.

BAT’s response highlights major flaws with the methodology and conclusions of the review including that it:

  • Fails to contextualize the risks of e-cigarettes relative to those associated with continued smoking.
  • Makes inaccurate claims regarding e-cigarettes many of which have been widely debunked by the scientific and public health communities.
  • Contains false assumptions that e-cigarette aerosol is the same as tobacco smoke.
  • Neglects landmark independent studies showing that many smokers view e-cigarettes as an acceptable alternative to smoking.
  • Relies on data from non-EU markets and studies on products pre-dating the current Tobacco Products Directive that are not relevant to the current EU context.

Said Eric Sensi-Minautier, VP EU Affairs at BAT , “If future regulations on vaping were to be based on the review as it stands now, they would be based on flawed evidence. We call on the SCHEER Committee to address the serious gaps in the review and reflect the weight of evidence supporting the harm reduction potential of e-cigarettes relative to continued smoking. It’s important that the Commission bases any change to the rules on vaping on accurate scientific advice that has been conducted to the highest standards, to make sure the millions of European vapers who use e-cigarettes as an alternative to smoking can continue to access them. We take the science around e-cigarettes seriously and are leading our own weight of evidence review to advance understanding of this growing product category.”

BAT highlights the need for greater transparency and cooperation between all stakeholders including industry, government, scientists, public health bodies and academics. Click here to read BAT’s response to the public consultation.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Riskified Analysis Reveals 1 in 4 Refund Dollars Is Abusive; Introduces "Dynamic Returns," a New Policy Protect Feature, to Safeguard Revenue While Increasing Customer Satisfaction12.1.2026 14:00:00 CET | Press release

Riskified (NYSE: RSKD) a leader in ecommerce fraud and risk intelligence, today released a research analysis highlighting a growing customer experience dilemma: As merchants tighten controls to fight a surge in return and refund abuse, they are inadvertently creating a more restrictive and frustrating experience for their best customers. To help retailers mitigate this challenge, Riskified has introduced a new feature in its Policy Protect solution, Dynamic Returns, AI-powered return decisions that adapt in real-time based on customer eligibility. Riskified's 2024 analysis of over a million refund claims found that 1-2% of total order value measured in sales dollars was requested back as refunds, with nearly 1 in 4 dollars claimed being abusive. In response to rising abuse, many retailers are implementing restrictive tactics like flat return fees, shorter return windows, and delaying refunds, often taking 10+ days for warehouse inspection. These measures frustrate good customers, as 68

Esri’s Custom Chart Builder Adopted by the Shom (French Hydrographic and Oceanographic Office) for Nautical Chart Production12.1.2026 14:00:00 CET | Press release

Geospatial Solution for Safety-Critical Maritime Use Sets Global Benchmark for Chart Automation Esri, the global leader in location intelligence, announced today that the Shom (French Hydrographic and Oceanographic Office) has officially adopted Custom Chart Builder (CCB) for automated production of all paper nautical charts. Following extensive testing and configuration, Shom confirmed that CCB-generated charts meet the stringent safety standards required by the French Navy, marking a pivotal advancement in automating maritime cartography and reinforcing its role as a pioneer in maritime digital transformation. “This adoption demonstrates that high-quality, regulation-compliant paper charts can now be produced without manual intervention, dramatically reducing production time and cost,” said Rafael Ponce, Esri principal maritime consultant. “Shom’s endorsement validates Esri’s CCB as a trusted solution for hydrographic offices worldwide, supporting the transition to digital-first work

Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands12.1.2026 13:30:00 CET | Press release

Cellares’ new IDMO Smart Factory in Leiden, Netherlands, expands commercial-scale manufacturing capacity for European cell therapy patient populations through a standardized, automated, and highly scalable facility model Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity. Cell therapy manufacturing is patient-specific and time-sensitive, making regional production capacity increasingly important as programs advance from clinical development toward commercial supply. The new Netherlands hub is designed to provide European drug developers with access to automated manufacturing infrastructure, while maintaining alignment to a common production stan

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas12.1.2026 13:30:00 CET | Press release

Updated national AAC protocol supports hospital-based, fully-reimbursed compassionate access across three solid tumor settings Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France’s National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol for botensilimab (BOT) plus balstilimab (BAL) under France’s Autorisation d’Accès Compassionnel (AAC) framework. The updated protocol expands France’s previously granted AAC authorization for BOT+BAL in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases to eligible patients with certain ovarian cancers and soft-tissue sarcomas—diseases with substantial unmet medical need after standard options have been exhausted. The revised protocol is designed to broaden the eligibility criteria, allowing more patients with advanced solid tumors to have early access to BOT+BAL under reimbursed compassionate

Lilac and Traxys Announce Binding 10-Year Offtake Agreement for Great Salt Lake Lithium Production12.1.2026 13:00:00 CET | Press release

Definitive agreement secures 100% of Phase 1 production, advancing project toward final investment decision Lilac Solutions, a leading provider of direct lithium extraction technology, and Traxys North America, a leading global physical trader and merchant in metals and natural resources, today announced a binding 10-year offtake agreement for lithium carbonate produced at Lilac's Great Salt Lake facility in Utah. The agreement represents a major milestone in advancing the project toward construction and establishes a clear commercial pathway for one of the nearest-term domestic lithium projects in the United States. Under the terms of the definitive agreement, Traxys will purchase 50,000 tonnes of lithium carbonate over a 10-year period, representing 100% of the planned Phase 1 production capacity. The agreement is take-or-pay, with agreed pricing mechanisms linked to market indices. The Great Salt Lake Phase 1 facility is designed to produce 5,000 tonnes per annum of battery-grade li

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye